AST SpaceMobile stock slides after Scotiabank downgrade calls valuation “irrational”
7 January 2026
1 min read

AST SpaceMobile stock slides after Scotiabank downgrade calls valuation “irrational”

New York, Jan 7, 2026, 12:42 (EST) — Regular session

AST SpaceMobile, Inc. (ASTS) fell 8.5% to $89.18 in midday trading on Wednesday after Scotiabank cut the satellite communications company to sector underperform. The stock opened at $91 and hit a session low of $88.49 as volume rose past 12.3 million shares.

The downgrade hits after a sharp run that has pushed the stock close to its highs and made valuation the central argument. Shares have more than tripled over the past 12 months, even though the company is not expected to post positive operating profit until 2027. 1

Scotiabank analyst Andres Coello set a $45.60 price target — a broker’s estimate of where the stock could trade over the next 12 months — and called the company’s roughly $37 billion valuation at Tuesday’s close “irrational.” He said AST has yet to sign a retail customer and may need around 50 satellites in orbit to offer continuous service in some markets by late 2026 or early 2027. Coello said meaningful free cash flow, or cash left after capital spending, may not show up until 2028 or 2029. 2

AST says it is building a space-based cellular broadband network using a constellation of BlueBird low-Earth-orbit satellites designed to connect directly with standard, unmodified phones for commercial and government use. 3

In the race to link phones from space, Starlink is the yardstick. Coello wrote that AST faces an “uphill battle” against SpaceX’s Starlink, noting that while AST has launched seven satellites since 2017, Starlink orbited 3,169 in 2025 alone. 4

Targets elsewhere on the Street sit far below the stock’s recent price. Data compiled by MarketBeat show the average analyst target at about $45.66. 5

But the call cuts both ways. If AST accelerates launches and converts early trials into paying usage sooner than expected, the stock’s premium could hold; if not, the market may start pricing in more dilution and a longer wait for cash.

The next marker is the quarterly update. The company has not confirmed the date, but market calendars show the next earnings report expected around March 2. 6

Stock Market Today

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
New York, Feb 7, 2026, 10:22 EST — Market closed. Eli Lilly and Company shares closed Friday up $37.34, or 3.7%, at $1,058.18. The move came as U.S. regulators sharpened their tone on “compounded” weight-loss drugs — pharmacy-made versions meant for shortages or special patient needs that have morphed into mass-market alternatives. The FDA said it would take action against telehealth firm Hims & Hers over a $49 pill it marketed as a Wegovy-like option, and Lilly said it “applauded” the agency’s action. 1 Why it matters now: obesity and diabetes medicines have become the growth engine for large drugmakers,
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

7 February 2026
Meta closed down 1.3% Friday at $661.46, capping a 6.4% weekly drop as investors questioned heavy AI spending. Amazon and Alphabet also fell after outlining major capital outlays. Meta’s Instagram suffered a brief outage this week. Legal risks persist, with trials involving Meta set for next week in Los Angeles and New Mexico.
Vedanta hits fresh 52-week high near Rs 630 on demerger trade; broker targets stretch to Rs 686
Previous Story

Vedanta hits fresh 52-week high near Rs 630 on demerger trade; broker targets stretch to Rs 686

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale
Next Story

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Go toTop